ELAN Q2 2019 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$782M+1.5% YoY

Gross Profit

$376M48.1% margin

Operating Income

$107M13.6% margin

Net Income

$36M4.6% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$29M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$8.9B

Total Liabilities

$3.6B

Stockholders' Equity

$5.3B

Cash & Equivalents

$385M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$782M	$770M	+1.5%
Gross Profit	$376M	$289M	+30.1%
Operating Income	$107M	$37M	+189.7%
Net Income	$36M	-$63M	+157.2%

Revenue Segments

Food Animal Ruminants And Swine

$272M35%

Companion Animal Disease Prevention

$223M29%

Food Animal Future Protein And Health

$176M22%

Companion Animal Therapeutics

$83M11%

Strategic Exits

$28M4%

Geographic Segments

UNITED STATES

$395M51%

Non-US

$387M49%